BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33579957)

  • 1. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms.
    Schwartz JR; Ma J; Kamens J; Westover T; Walsh MP; Brady SW; Robert Michael J; Chen X; Montefiori L; Song G; Wu G; Wu H; Branstetter C; Hiltenbrand R; Walsh MF; Nichols KE; Maciaszek JL; Liu Y; Kumar P; Easton J; Newman S; Rubnitz JE; Mullighan CG; Pounds S; Zhang J; Gruber T; Ma X; Klco JM
    Nat Commun; 2021 Feb; 12(1):985. PubMed ID: 33579957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
    Hartmann L; Nadarajah N; Meggendorfer M; Höllein A; Vetro C; Kern W; Haferlach T; Haferlach C; Stengel A
    Leukemia; 2020 Mar; 34(3):811-820. PubMed ID: 31719678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CBL mutation in childhood therapy-related leukemia.
    Shiba N; Taki T; Park MJ; Nagasawa M; Kanazawa T; Takita J; Ohnishi H; Sotomatsu M; Arakawa H; Hayashi Y
    Leukemia; 2011 Aug; 25(8):1356-8. PubMed ID: 21494262
    [No Abstract]   [Full Text] [Related]  

  • 5. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
    Xie W; Tang G; Wang E; Kim Y; Cloe A; Shen Q; Zhou Y; Garcia-Manero G; Loghavi S; Hu AY; Wang S; Bueso-Ramos CE; Kantarjian HM; Medeiros LJ; Hu S
    Ann Hematol; 2020 Mar; 99(3):487-500. PubMed ID: 32006151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA sequencing reveals a unique fusion of the lysine (K)-specific methyltransferase 2A and smooth muscle myosin heavy chain 11 in myelodysplastic syndrome and acute myeloid leukemia.
    Sanders MA; Kavelaars FG; Zeilemaker A; Al Hinai AS; Abbas S; Beverloo HB; van Lom K; Valk PJ
    Haematologica; 2015 Jan; 100(1):e1-3. PubMed ID: 25552680
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy-related myeloid neoplasms: what's in a name?
    Klimek VM; Tray NJ
    Curr Opin Hematol; 2016 Mar; 23(2):161-6. PubMed ID: 26779614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
    Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
    Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia.
    Cerveira N; Santos J; Bizarro S; Costa V; Ribeiro FR; Lisboa S; Correia C; Torres L; Vieira J; Snijder S; Mariz JM; Norton L; Mellink CH; Buijs A; Teixeira MR
    BMC Cancer; 2009 May; 9():147. PubMed ID: 19445675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and outcome of children with treatment related acute myeloid leukemia.
    Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D
    Pediatr Blood Cancer; 2008 Jan; 50(1):17-23. PubMed ID: 17252569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Sakhdari A; Tang Z; Ok CY; Bueso-Ramos CE; Medeiros LJ; Huh YO
    Cancer Genet; 2019 Oct; 238():18-22. PubMed ID: 31425921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
    Gibson CJ; Lindsley RC; Tchekmedyian V; Mar BG; Shi J; Jaiswal S; Bosworth A; Francisco L; He J; Bansal A; Morgan EA; Lacasce AS; Freedman AS; Fisher DC; Jacobsen E; Armand P; Alyea EP; Koreth J; Ho V; Soiffer RJ; Antin JH; Ritz J; Nikiforow S; Forman SJ; Michor F; Neuberg D; Bhatia R; Bhatia S; Ebert BL
    J Clin Oncol; 2017 May; 35(14):1598-1605. PubMed ID: 28068180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
    Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ
    Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia.
    Rautenberg C; Germing U; Stepanow S; Lauseker M; Köhrer K; Jäger PS; Geyh S; Fan M; Haas R; Kobbe G; Schroeder T
    Am J Hematol; 2021 Jan; 96(1):E15-E17. PubMed ID: 33017477
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
    Diamond B; Ziccheddu B; Maclachlan K; Taylor J; Boyle E; Ossa JA; Jahn J; Affer M; Totiger TM; Coffey D; Chandhok N; Watts J; Cimmino L; Lu SX; Bolli N; Bolton K; Landau H; Park JH; Ganesh K; McPherson A; Sekeres MA; Lesokhin A; Chung DJ; Zhang Y; Ho C; Roshal M; Tyner J; Nimer S; Papaemmanuil E; Usmani S; Morgan G; Landgren O; Maura F
    Blood; 2023 May; 141(19):2359-2371. PubMed ID: 36626250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
    Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
    Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
    Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
    Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
    Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
    Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.